ALXO
Alx Oncology Holdings Inc
$2.13
+0.07 (+3.16%)
At close · Jul 10
Market Cap
$285.95M
Shares
134,562,917
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.13
Open$2.08
Day$2.00–2.17
52W$0.44–2.66
Avg vol 30d1.6M
Short int6.3M · 4.7% float · 2.1d
Short vol65%
Last earningsMay 8, 2026
DataJul 2020–Jul 2026
Filing10-Q · May 8
Up next
Next earnings call
Aug 8, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+14%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
76%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+46%
trailing
6-month return
+76%
trailing
YTD return
+88%
this year
Relative strength
+67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +24 funds added
Insider flow
Distributing
Net -$2.9K over 90 days · 100% sells
Short interest
Rising
4.70% of float · ▲ +144.0% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
EPS growth
+26%
Y/Y
Free cash flow
$-84.4M
Balance sheet
$6.2M
net cash
Quant / Vol
risk profile
Volatility
118%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
76%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +24 funds added
Insider flow
Distributing
Net -$2.9K over 90 days · 100% sells
Short interest
Rising
4.70% of float · ▲ +144.0% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $2 · 76%
52-wk high $3
vs 200-day avg +22%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALXO
this stock
Alx Oncology Holdings Inc
|
$285.95M | +88.1% | -75.4% | — | 4.7% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +9.5% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALXO | +2.7% | +45.6% | +75.6% | +2.7% | +88.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +1.3% | +41.5% | +66.6% | +1.6% | +77.3% |